Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, So… Read more
Boryung Pharm (003850) - Total Liabilities
Latest total liabilities as of September 2025: ₩537.67 Billion KRW
Based on the latest financial reports, Boryung Pharm (003850) has total liabilities worth ₩537.67 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Boryung Pharm - Total Liabilities Trend (2009–2024)
This chart illustrates how Boryung Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Boryung Pharm Competitors by Total Liabilities
The table below lists competitors of Boryung Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Steyr Motors AG
VI:4X0
|
Austria | €4.51 Million |
|
Vizionfocus Inc.
TW:4771
|
Taiwan | NT$2.44 Billion |
|
John Mattson Fastighetsforetagen AB
ST:JOMA
|
Sweden | Skr8.78 Billion |
|
Protara Therapeutics Inc
NASDAQ:TARA
|
USA | $12.35 Million |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
USA | $102.49 Million |
|
Curacle Co. Ltd.
KQ:365270
|
Korea | ₩16.67 Billion |
|
NEXCOM International Co Ltd
TWO:8234
|
Taiwan | NT$2.75 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Boryung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Boryung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Boryung Pharm (2009–2024)
The table below shows the annual total liabilities of Boryung Pharm from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩379.58 Billion | +3.64% |
| 2023-12-31 | ₩366.26 Billion | -2.58% |
| 2022-12-31 | ₩375.97 Billion | +6.11% |
| 2021-12-31 | ₩354.33 Billion | +15.15% |
| 2020-12-31 | ₩307.71 Billion | +36.96% |
| 2019-12-31 | ₩224.68 Billion | +15.86% |
| 2018-12-31 | ₩193.91 Billion | +26.86% |
| 2017-12-31 | ₩152.86 Billion | -24.53% |
| 2016-12-31 | ₩202.55 Billion | +59.22% |
| 2012-12-31 | ₩127.21 Billion | +2.25% |
| 2011-12-31 | ₩124.42 Billion | +13.68% |
| 2010-12-31 | ₩109.45 Billion | +107.40% |
| 2009-12-31 | ₩52.77 Billion | -- |